- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00424294
A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis
2014년 9월 10일 업데이트: Pfizer
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of CP-195543 And Celecoxib Dual Therapy In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis In Subjects Who Are Inadequately Controlled On Methotrexate
To evaluate the efficacy, safety and tolerability of CP-195543 and celecoxib dual therapy in subjects with rheumatoid arthritis
연구 개요
상세 설명
Trial enrollment was prematurely discontinued on December 3, 2007.
The results of an interim efficacy and safety analysis demonstrated an overall poor tolerability profile and high discontinuation rate when dual therapy with CP-195543 and Celecoxib was administered.
The decision to discontinue further enrollment in the trial was not based on any efficacy or serious safety concerns.
Previously enrolled study participants continued in the study and the trial completed on February 27, 2008.
연구 유형
중재적
등록 (실제)
70
단계
- 2 단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
Alabama
-
Huntsville, Alabama, 미국, 35801
- Pfizer Investigational Site
-
-
Arizona
-
Scottsdale, Arizona, 미국, 85251
- Pfizer Investigational Site
-
-
California
-
Upland, California, 미국, 91786
- Pfizer Investigational Site
-
-
Florida
-
Boca Raton, Florida, 미국, 33486
- Pfizer Investigational Site
-
Clearwater, Florida, 미국, 33765
- Pfizer Investigational Site
-
Dunedin, Florida, 미국, 34698
- Pfizer Investigational Site
-
Fort Lauderdale, Florida, 미국, 33334
- Pfizer Investigational Site
-
Lake Mary, Florida, 미국, 32746
- Pfizer Investigational Site
-
Miramar, Florida, 미국, 33025
- Pfizer Investigational Site
-
New Port Richey, Florida, 미국, 34652
- Pfizer Investigational Site
-
Orange City, Florida, 미국, 32763
- Pfizer Investigational Site
-
Orlando, Florida, 미국, 32804
- Pfizer Investigational Site
-
Port Richey, Florida, 미국, 34668
- Pfizer Investigational Site
-
Sarasota, Florida, 미국, 34233
- Pfizer Investigational Site
-
Sarasota, Florida, 미국, 34239
- Pfizer Investigational Site
-
Tampa, Florida, 미국, 33614-7118
- Pfizer Investigational Site
-
Venice, Florida, 미국, 34292
- Pfizer Investigational Site
-
Vero Beach, Florida, 미국, 32960
- Pfizer Investigational Site
-
-
Illinois
-
Moline, Illinois, 미국, 61265
- Pfizer Investigational Site
-
Springfield, Illinois, 미국, 62704
- Pfizer Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46250
- Pfizer Investigational Site
-
Munster, Indiana, 미국, 46321
- Pfizer Investigational Site
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40504
- Pfizer Investigational Site
-
-
Louisiana
-
Covington, Louisiana, 미국, 70433
- Pfizer Investigational Site
-
New Orleans, Louisiana, 미국, 70115
- Pfizer Investigational Site
-
-
Maryland
-
Frederick, Maryland, 미국, 21702
- Pfizer Investigational Site
-
-
Michigan
-
Kalamazoo, Michigan, 미국, 49009
- Pfizer Investigational Site
-
-
Mississippi
-
Tupelo, Mississippi, 미국, 38801
- Pfizer Investigational Site
-
-
Missouri
-
Springfield, Missouri, 미국, 65807
- Pfizer Investigational Site
-
-
New York
-
Olean, New York, 미국, 14760
- Pfizer Investigational Site
-
Rochester, New York, 미국, 14618
- Pfizer Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73139
- Pfizer Investigational Site
-
-
Pennsylvania
-
Philladelphia, Pennsylvania, 미국, 19118
- Pfizer Investigational Site
-
-
Tennessee
-
Knoxville, Tennessee, 미국, 37909-1600
- Pfizer Investigational Site
-
Memphis, Tennessee, 미국, 38119
- Pfizer Investigational Site
-
-
Texas
-
Houston, Texas, 미국, 77090
- Pfizer Investigational Site
-
Killeen, Texas, 미국, 76549
- Pfizer Investigational Site
-
San Antonio, Texas, 미국, 78217
- Pfizer Investigational Site
-
-
Utah
-
Ogden, Utah, 미국, 84403
- Pfizer Investigational Site
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- A diagnosis of RA based upon the American college of Rheumatology 1987 revised criteria
- Active disease at Screening
- Stable dose of methotrexate between 10-25 mg/week oral or parenteral
Exclusion Criteria:
- A diagnosis of any other inflammatory or secondary, noninflammatory arthritis that, in the opinion of the Investigator, would interfere with disease activity assessments
- A history of hypersensitivity or allergic type reactions to cyclooxygenase inhibitors, opiates, aspirin or sulfonamides
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
활성 비교기: Celecoxib
Celecoxib with placebo therapy.
|
Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States [US] as Celeberex) and approved for the relief of signs and symptoms of osteoarthritis.
|
다른: Methotrexate
Background Methotrexate taken in both CP-195,543/Celecoxib and Celecoxib only arms.
|
Methotrexate is a folate analogue that, based on it efficacy and safety in RA, is commonly used as frontline DMARD treatment in patients with moderate to severe disease who do not respond to NSAIDs alone.
|
실험적: CP-195,543
CP-195,543 and Celecoxib dual therapy.
|
CP-195543 is a potent and specific antagonist of the leukotriene B4 (LTB4) receptor.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12
기간: Week 12
|
ACR20 response: greater than or equal to (>=) 20 percent (%) improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).
|
Week 12
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 1, 2, 4 and 8
기간: Week 1, 2, 4, 8
|
ACR20 response: >=20% improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).
|
Week 1, 2, 4, 8
|
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response
기간: Week 1, 2, 4, 8, 12
|
ACR50 response: >=50% improvement in tender joint count; >=50% improvement in swollen joint count; and >=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).
|
Week 1, 2, 4, 8, 12
|
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response
기간: Week 1, 2, 4, 8, 12
|
ACR70 response: >=70% improvement in tender joint count; >=70% improvement in swollen joint count; and >=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).
|
Week 1, 2, 4, 8, 12
|
Change From Baseline in Tender/Painful Joint Count (TJC) at Week 1, 2, 4, 8 and 12
기간: Baseline, Week 1, 2, 4, 8, 12
|
Participants were assessed for tender/painful joints using a 28-joint count comprised of left and right shoulders, elbows, wrists, proximal interphalangeal joints, metacarpophalangeal joints and knees.
Artificial joints were not assessed.
|
Baseline, Week 1, 2, 4, 8, 12
|
Change From Baseline in Swollen Joint Count (SJC) at Week 1, 2, 4, 8 and 12
기간: Baseline, Week 1, 2, 4, 8, 12
|
Participants were assessed for swollen joints using a 28-joint count comprised of left and right shoulders, elbows, wrists, proximal interphalangeal joints, metacarpophalangeal joints and knees.
Artificial joints were not assessed.
|
Baseline, Week 1, 2, 4, 8, 12
|
Change From Baseline in Patient's Assessment of Arthritis Pain at Week 1, 2, 4, 8 and 12
기간: Baseline, Week 1, 2, 4, 8, 12
|
Patient's assessment of arthritis pain was assessed using a 100 millimeter (mm) visual analogue scale (VAS) with range: 0 = no pain to 100 = worst possible pain.
|
Baseline, Week 1, 2, 4, 8, 12
|
Change From Baseline in Patient's Global Assessment of Arthritis at Week 1, 2, 4, 8 and 12
기간: Baseline, Week 1, 2, 4, 8, 12
|
Patient's global assessment of arthritic condition assessed all the ways participants' illness and health conditions affect them at the time of assessment.
The response was scored on a 5-point scale: 1 = Very Good (Asymptomatic and no limitation of normal activities), 2 = Good (Mild symptoms and no limitation of normal activities), 3 = Fair (Moderate symptoms and limitation of some normal activities), 4 = Poor (Severe symptoms and inability to carry out most normal activities) and 5 = Very Poor (Very severe symptoms which are intolerable and inability to carry out all normal activities).
|
Baseline, Week 1, 2, 4, 8, 12
|
Change From Baseline in Physician's Global Assessment of Arthritis at Week 1, 2, 4, 8 and 12
기간: Baseline, Week 1, 2, 4, 8, 12
|
Investigator assessed overall appearance of arthritis at the time of the visit.
The response was scored on a 5-point scale: 1 = Very Good (Asymptomatic and no limitation of normal activities), 2 = Good (Mild symptoms and no limitation of normal activities), 3 = Fair (Moderate symptoms and limitation of some normal activities), 4 = Poor (Severe symptoms and inability to carry out most normal activities) and 5 = Very Poor (Very severe symptoms which are intolerable and inability to carry out all normal activities).
|
Baseline, Week 1, 2, 4, 8, 12
|
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 1, 2, 4, 8 and 12
기간: Baseline, Week 1, 2, 4, 8, 12
|
Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week.
Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do.
Overall score was computed as the sum of domain scores and divided by the number of domains answered.
Total possible score range 0-3, where 0 = least difficulty and 3 = extreme difficulty.
|
Baseline, Week 1, 2, 4, 8, 12
|
Change From Baseline in C-Reactive Protein (CRP) at Week 1, 2, 4, 8 and 12
기간: Baseline, Week 1, 2, 4, 8, 12
|
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay.
A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
|
Baseline, Week 1, 2, 4, 8, 12
|
Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 1, 2, 4, 8 and 12
기간: Baseline, Week 1, 2, 4, 8, 12
|
DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP.
It was calculated as DAS28-3 (CRP) = 1.15 + 1.10 * ([0.56 * square root of TJC] + [0.28 * square root of SJC] + [0.36 * natural logarithm of {CRP+1}]).
Total score range: 0 to 9.4, higher score indicated more disease activity.
DAS28-3 (CRP) <= 3.2 implied low disease activity and >3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) <2.6 = remission.
|
Baseline, Week 1, 2, 4, 8, 12
|
Change From Baseline in Duration of Morning Stiffness at Week 1, 2, 4, 8 and 12
기간: Baseline, Week 1, 2, 4, 8, 12
|
Duration of morning stiffness was defined as the time elapsed between the time participant woke up and was able to resume normal activities without stiffness in hours (duration was recorded in hours to the nearest quarter.
For those participants with unrelenting stiffness, duration was recorded as 24 hours).
|
Baseline, Week 1, 2, 4, 8, 12
|
Number of Participants Who Withdrew From Study Due to Lack of Efficacy
기간: Baseline up to Week 12
|
Baseline up to Week 12
|
|
Time to Withdrawal Due to Lack of Efficacy
기간: Baseline up to Week 12
|
Baseline up to Week 12
|
|
Number of Participants With Clinical Laboratory Abnormalities
기간: Baseline up to Week 13
|
Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); liver function (aspartate aminotransferase, alanine aminotransferase, total bilirubin, lactate dehydrogenase, alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine, uric acid); electrolytes (sodium, potassium, chloride, calcium, phosphate, bicarbonate); clinical chemistry (glucose, creatine kinase); immunology (CRP); urinalysis (dipstick [urine specific gravity, decimal logarithm of reciprocal of hydrogen ion activity {pH} of urine, glucose, protein, blood, ketones, bilirubin], microscopy [urine RBC, WBC, urate crystals, calcium, oxalate, miscellaneous [urine mucus and leucocytes]).
|
Baseline up to Week 13
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
기간: Baseline up to 28 days after last dose
|
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug.
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
|
Baseline up to 28 days after last dose
|
Number of Adverse Events by Severity
기간: Baseline up to 28 days after last dose
|
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug.
AEs are classified according to the severity in 3 categories a) mild - AEs does not interfere with participant's usual function b) moderate - AEs interferes to some extent with participant's usual function c) severe - AEs interferes significantly with participant's usual function.
|
Baseline up to 28 days after last dose
|
Change From Baseline in Systolic and Diastolic Blood Pressure at Day 7, 14, 21, 28, 42, 56, 84 and 91
기간: Baseline, Day 7, 14, 21, 28, 42, 56, 84, 91
|
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were evaluated in sitting position.
|
Baseline, Day 7, 14, 21, 28, 42, 56, 84, 91
|
Change From Baseline in Heart Rate Day 7, 14, 21, 28, 42, 56, 84 and 91
기간: Baseline, Day 7, 14, 21, 28, 42, 56, 84, 91
|
Baseline, Day 7, 14, 21, 28, 42, 56, 84, 91
|
|
Number of Participants With Abnormal Electrocardiogram (ECG)
기간: Baseline up to Week 12
|
Criteria for potential clinical concern in ECG parameters: Maximum corrected QT interval (QTc) in range of 450 to less than 480 millisecond (msec), Maximum QTcB interval (Bazett's Correction) (msec) in range of 450 to less than 480 msec, Maximum QTcF interval (Fridericia's Correction) in range of 450 to less than 480 msec, maximum QTc interval increase from baseline in range of 30 to less than 60 msec and >=60 msec.
|
Baseline up to Week 12
|
Number of Participants With Categorical Vital Signs Data
기간: Baseline, Week 12
|
Number of participants with maximum increase from Baseline in sitting SBP and DBP of greater than or equal to 30 mmHg at Week 12 was reported.
|
Baseline, Week 12
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2006년 6월 1일
기본 완료 (실제)
2007년 12월 1일
연구 완료 (실제)
2008년 2월 1일
연구 등록 날짜
최초 제출
2007년 1월 18일
QC 기준을 충족하는 최초 제출
2007년 1월 18일
처음 게시됨 (추정)
2007년 1월 19일
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
2014년 9월 25일
QC 기준을 충족하는 마지막 업데이트 제출
2014년 9월 10일
마지막으로 확인됨
2014년 9월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- A7701005
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
celecoxib에 대한 임상 시험
-
Seoul National University HospitalSeoul National University Bundang Hospital알려지지 않은
-
University of British ColumbiaObsessive Compulsive Foundation; BC Children's Hospital Research Institute모병